Cartesian Therapeutics Inc. (RNAC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $193.69M
Last updated: Nov 17, 2026 at 11:05 AM ET
Cartesian Therapeutics Inc. (RNAC) Earnings: Report Dates and Results
Cartesian Therapeutics (RNAC) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Cartesian Therapeutics reported EPS of -$0.38, above the -$1.02 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RNAC has an expected report date of Mar 8, 2027.
Earnings History
Of the 40 quarters below that had an estimate, RNAC beat 23, missed 16 and matched 1. The widest gap in the table came in the quarter ended Jun 30, 2024, when EPS landed 811.11% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.38 | -$1.02 | N/A | +62.75% | Beat | N/A | 1 | 0 up, 1 down | Nov 5, 2026 | N/A |
| Jun 30, 2026 | $0.46 | -$0.83 | N/A | +155.42% | Beat | -8.0% | 1 | 1 up, 0 down | Aug 6, 2026 | N/A |
| Mar 31, 2026 | -$0.95 | -$0.70 | -$0.70 - -$0.70 | -35.71% | Miss | N/A | 1 | 0 up, 0 down | Apr 30, 2026 | $78000 |
| Dec 31, 2025 | -$2.71 | -$0.79 | -$0.79 - -$0.79 | -242.59% | Miss | N/A | 1 | N/A | Mar 9, 2026 | $947000 |
| Sep 30, 2025 | -$0.73 | -$0.63 | -$0.63 - -$0.63 | -15.87% | Miss | N/A | 1 | N/A | Nov 6, 2025 | $452000 |
| Jun 30, 2025 | $0.50 | -$0.76 | N/A | +165.79% | Beat | -21.9% | 1 | 0 up, 0 down | Aug 7, 2025 | $298000 |
| Mar 31, 2025 | -$0.65 | -$0.71 | N/A | +8.45% | Beat | N/A | N/A | 0 up, 0 down | May 8, 2025 | $1.10M |
| Dec 31, 2024 | -$0.59 | -$0.83 | -$1.05 - -$0.61 | +28.12% | Beat | N/A | 5 | 2 up, 2 down | Mar 20, 2025 | N/A |
| Sep 30, 2024 | -$0.42 | -$0.55 | -$0.97 - -$0.55 | +23.64% | Beat | N/A | 5 | 0 up, 0 down | Nov 7, 2024 | $387000 |
| Jun 30, 2024 | $0.64 | -$0.09 | N/A | +811.11% | Beat | N/A | 6 | 0 up, 0 down | Aug 8, 2024 | $33.45M |
| Mar 31, 2024 | -$0.80 | -$1.42 | -$1.50 - -$0.27 | +43.66% | Beat | N/A | 4 | 1 up, 0 down | May 8, 2024 | $5.84M |
| Dec 31, 2023 | -$0.07 | -$0.04 | -$0.05 - -$0.02 | -75.00% | Miss | -275.0% | 2 | 0 up, 0 down | Mar 7, 2024 | $8.27M |
| Sep 30, 2023 | -$0.06 | -$0.06 | -$0.10 - $0.04 | 0.00% | In line | N/A | 6 | 0 up, 0 down | Nov 13, 2023 | $6.55M |
| Jun 30, 2023 | -$0.07 | -$0.08 | -$0.12 - $0.03 | +12.50% | Beat | -216.7% | 6 | 0 up, 0 down | Aug 17, 2023 | $5.25M |
| Mar 31, 2023 | -$0.14 | -$0.09 | -$0.14 - -$0.01 | -55.56% | Miss | -160.9% | 7 | 0 up, 0 down | May 4, 2023 | $5.94M |
| Dec 31, 2022 | $0.04 | -$0.07 | -$0.14 - -$0.03 | +157.14% | Beat | +33.3% | 7 | 1 up, 0 down | Mar 30, 2023 | $16.80M |
| Sep 30, 2022 | -$0.05 | -$0.01 | -$0.09 - $0.12 | -400.00% | Miss | N/A | 7 | 0 up, 0 down | Dec 29, 2022 | $20.71M |
| Jun 30, 2022 | $0.06 | -$0.08 | N/A | +175.00% | Beat | +50.0% | N/A | 1 up, 0 down | Sep 28, 2022 | $39.27M |
| Mar 31, 2022 | $0.23 | -$0.11 | -$0.21 - -$0.07 | +309.09% | Beat | N/A | 6 | 0 up, 0 down | Jun 28, 2022 | $34.00M |
| Dec 31, 2021 | $0.03 | -$0.07 | -$0.14 - -$0.02 | +142.86% | Beat | N/A | 7 | N/A | Mar 29, 2022 | $29.94M |
| Sep 30, 2021 | -$0.16 | -$0.07 | -$0.18 - $0.00 | -128.57% | Miss | N/A | 7 | 4 up, 0 down | Dec 29, 2021 | $24.43M |
| Jun 30, 2021 | $0.04 | -$0.12 | -$0.19 - -$0.06 | +133.33% | Beat | N/A | 7 | N/A | Sep 28, 2021 | $19.66M |
| Mar 31, 2021 | -$0.22 | -$0.12 | -$0.16 - -$0.08 | -83.33% | Miss | N/A | 5 | N/A | Jun 28, 2021 | $11.05M |
| Dec 31, 2020 | -$0.14 | -$0.12 | -$0.18 - -$0.07 | -16.67% | Miss | N/A | 6 | N/A | Mar 29, 2021 | $11.95M |
| Sep 30, 2020 | -$0.09 | $0.06 | -$0.15 - $0.65 | -250.00% | Miss | N/A | 7 | N/A | Nov 5, 2020 | $4.65M |
| Jun 30, 2020 | -$0.25 | -$0.30 | -$6.61 - $17.72 | +16.75% | Beat | N/A | 8 | N/A | Aug 6, 2020 | N/A |
| Mar 31, 2020 | -$0.21 | -$0.28 | -$0.41 - -$0.18 | +25.00% | Beat | N/A | 8 | N/A | May 7, 2020 | N/A |
| Dec 31, 2019 | -$0.30 | -$0.21 | -$0.28 - -$0.11 | -42.86% | Miss | N/A | 7 | N/A | Mar 12, 2020 | $6.65M |
| Sep 30, 2019 | -$0.26 | -$0.33 | -$0.37 - -$0.28 | +21.21% | Beat | N/A | 5 | N/A | Nov 8, 2019 | N/A |
| Jun 30, 2019 | -$0.37 | -$0.30 | -$0.41 - -$0.25 | -23.33% | Miss | N/A | 5 | N/A | Aug 8, 2019 | $13000 |
| Mar 31, 2019 | -$0.31 | -$0.35 | -$0.37 - -$0.31 | +11.43% | Beat | N/A | 5 | N/A | May 9, 2019 | $10000 |
| Dec 31, 2018 | -$0.65 | -$0.70 | -$0.76 - -$0.54 | +7.14% | Beat | N/A | 5 | N/A | Mar 31, 2019 | $903000 |
| Sep 30, 2018 | -$0.71 | -$0.75 | -$0.87 - -$0.49 | +5.33% | Beat | N/A | 6 | N/A | Nov 8, 2018 | N/A |
| Jun 30, 2018 | -$0.84 | -$0.68 | -$0.78 - -$0.45 | -23.53% | Miss | N/A | 5 | N/A | Aug 8, 2018 | N/A |
| Mar 31, 2018 | -$0.71 | -$0.54 | -$0.72 - -$0.35 | -31.48% | Miss | N/A | 4 | N/A | May 9, 2018 | N/A |
| Dec 31, 2017 | -$0.88 | -$0.56 | -$1.12 - $0.00 | -57.14% | Miss | N/A | 4 | N/A | Mar 31, 2018 | $17000 |
| Sep 30, 2017 | -$0.63 | -$0.87 | N/A | +27.59% | Beat | N/A | N/A | N/A | Nov 7, 2017 | $27000 |
| Jun 30, 2017 | -$0.85 | -$0.90 | N/A | +5.56% | Beat | N/A | N/A | N/A | Aug 11, 2017 | $26000 |
| Mar 31, 2017 | -$0.82 | -$1.28 | N/A | +35.94% | Beat | N/A | N/A | N/A | May 11, 2017 | $137000 |
| Dec 31, 2016 | -$0.77 | -$0.25 | N/A | -208.00% | Miss | N/A | N/A | N/A | Mar 31, 2017 | $2.93M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.59, after -$1.17 the year before. It was -$3.95 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.59 | N/A |
| Dec 31, 2024 | -$1.17 | N/A |
| Dec 31, 2023 | -$0.34 | -221.4% |
| Dec 31, 2022 | $0.28 | N/A |
| Dec 31, 2021 | -$0.31 | N/A |
| Dec 31, 2020 | -$0.69 | N/A |
| Dec 31, 2019 | -$1.24 | N/A |
| Dec 31, 2018 | -$2.91 | N/A |
| Dec 31, 2017 | -$3.18 | N/A |
| Dec 31, 2016 | -$3.95 | N/A |
Frequently Asked Questions About RNAC
When is Cartesian Therapeutics's next earnings date?
Cartesian Therapeutics's next earnings report is expected for Mar 8, 2027.
Did RNAC beat earnings estimates last quarter?
Yes. Cartesian Therapeutics reported EPS of -$0.38 for the quarter ended Sep 30, 2026, above the -$1.02 estimate, a 62.75% surprise.
What EPS do analysts expect from RNAC next quarter?
The consensus EPS estimate for Cartesian Therapeutics for the quarter ending Dec 31, 2026 is -$0.95 from 9 analysts, with estimates from -$1.18 to -$0.41.
How often does RNAC beat earnings estimates?
Cartesian Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +15.79%.
RNAC pages: Overview, Earnings, Forecast, Financials, Competitors